The Human Resources Ministry will continue engaging with key stakeholders, including employers and employees, to refine the ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

The Human Resources Ministry (KESUMA) will continue engaging with key stakeholders, including employers and employees, to ...

They are also planning or starting phase 3 trials for other complement-mediated diseases, immune complex membranoproliferative glomerulonephritis (IC-MPGN), C3 glomerulopathy (C3G) and cold ...

The company also expects to submit a supplemental New Drug Application to the FDA for Empaveli for the treatment of the rare kidney diseases C3G and primary IC-MPGN in early 2025, with a potential ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Apellis Pharmaceuticals reports $709 million in 2024 U.S. net product revenues, anticipates new drug submissions and organizational changes. Apellis Pharmaceuticals announced preliminary U.S. net ...

Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net ...

Apellis Pharmaceuticals, Inc.（纳斯达克代码：APLS）的首席人事官Karen Lewis最近出售了1,241股普通股。该公司是一家市值37.5亿美元的生物科技公司。股票以每股29.96美元的平均价格出售，总计约37,178美元。这笔交易发生在2025年1月17日，当时公司股价在过去一周上涨了8.11%。出售后，Lewis仍持有43,858股。根据 ...